{"id":"fmx103-1-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FMX103 delivers minocycline, a tetracycline antibiotic with anti-inflammatory properties, directly to affected skin areas. The drug works by inhibiting bacterial growth and suppressing inflammatory pathways involved in acne and rosacea pathogenesis. The 1.5% concentration is optimized for topical efficacy while minimizing systemic absorption.","oneSentence":"FMX103 is a topical minocycline formulation that reduces bacterial colonization and inflammatory mediators in the skin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:57.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"},{"name":"Rosacea"}]},"trialDetails":[{"nctId":"NCT03276936","phase":"PHASE3","title":"A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-09-05","conditions":"Papulopustular Rosacea","enrollment":504},{"nctId":"NCT03142451","phase":"PHASE3","title":"A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-06-02","conditions":"Facial Papulopustular Rosacea","enrollment":751},{"nctId":"NCT04608500","phase":"PHASE3","title":"A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-06-01","conditions":"Facial Papulopustular Rosacea","enrollment":771},{"nctId":"NCT02601963","phase":"PHASE2","title":"Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2015-09","conditions":"Rosacea, Papulopustular Rosacea","enrollment":233}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FMX103 1.5%","genericName":"FMX103 1.5%","companyName":"Vyne Therapeutics Inc.","companyId":"vyne-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FMX103 is a topical minocycline formulation that reduces bacterial colonization and inflammatory mediators in the skin. Used for Acne vulgaris, Rosacea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}